uniQure N.V. (0EE0.L)

USD 16.7

(1.06%)

Gross Profit Summary of uniQure N.V.

  • uniQure N.V.'s latest annual gross profit in 2023 was 2.21 Million USD , down -97.85% from previous year.
  • uniQure N.V.'s latest quarterly gross profit in 2024 Q3 was 2.02 Million USD , up 27.24% from previous quarter.
  • uniQure N.V. reported a annual gross profit of 103.14 Million USD in annual gross profit 2022, down -79.33% from previous year.
  • uniQure N.V. reported a annual gross profit of 499.02 Million USD in annual gross profit 2021, up 687.88% from previous year.
  • uniQure N.V. reported a quarterly gross profit of -3.37 Million USD for 2024 Q1, down -57.04% from previous quarter.
  • uniQure N.V. reported a quarterly gross profit of 995 Thousand USD for 2024 Q2, up 129.53% from previous quarter.

Annual Gross Profit Chart of uniQure N.V. (2023 - 2011)

Historical Annual Gross Profit of uniQure N.V. (2023 - 2011)

Year Gross Profit Gross Profit Growth
2023 2.21 Million USD -97.85%
2022 103.14 Million USD -79.33%
2021 499.02 Million USD 687.88%
2020 -84.88 Million USD 2.94%
2019 -87.45 Million USD -41.57%
2018 -61.77 Million USD -13.76%
2017 -54.3 Million USD -14.1%
2016 -47.59 Million USD -592.37%
2015 9.66 Million USD 125.52%
2014 -37.87 Million USD -1380.07%
2013 2.95 Million USD 121.94%
2012 -13.48 Million USD 0.0%
2011 - USD 0.0%

Peer Gross Profit Comparison of uniQure N.V.

Name Gross Profit Gross Profit Difference
Editas Medicine, Inc. -99.52 Million USD 102.226%
Dynavax Technologies Corporation 182.11 Million USD 98.784%
Supernus Pharmaceuticals, Inc. 523.74 Million USD 99.577%
Perrigo Company plc 1.68 Billion USD 99.868%
Illumina, Inc. 2.74 Billion USD 99.919%
Thermo Fisher Scientific Inc. 15.22 Billion USD 99.985%
Iovance Biotherapeutics, Inc. -9.56 Million USD 123.155%
Walgreens Boots Alliance, Inc. 26.52 Billion USD 99.992%
IQVIA Holdings Inc. 5.23 Billion USD 99.958%
Heron Therapeutics, Inc. 10.04 Million USD 77.943%
Regeneron Pharmaceuticals, Inc. 11.3 Billion USD 99.98%
Unity Biotechnology, Inc. -19.69 Million USD 111.244%
Waters Corporation 1.76 Billion USD 99.874%
Biogen Inc. 7.3 Billion USD 99.97%
Sangamo Therapeutics, Inc. -45.32 Million USD 104.887%
Evolus, Inc. 140.52 Million USD 98.424%
Adicet Bio, Inc. -6.09 Million USD 136.323%
Cara Therapeutics, Inc. 14.79 Million USD 85.028%
bluebird bio, Inc. -4.03 Million USD 154.963%
Esperion Therapeutics, Inc. 73.06 Million USD 96.969%
FibroGen, Inc. 128.9 Million USD 98.282%
Agilent Technologies, Inc. 3.46 Billion USD 99.936%
Corbus Pharmaceuticals Holdings, Inc. -31.16 Million USD 107.107%
Homology Medicines, Inc. -7.22 Million USD 130.64%
Geron Corporation -123.5 Million USD 101.793%
Alnylam Pharmaceuticals, Inc. 1.51 Billion USD 99.854%
Amicus Therapeutics, Inc. 362.03 Million USD 99.388%
Myriad Genetics, Inc. 476.4 Million USD 99.535%
Viking Therapeutics, Inc. -292 Thousand USD 858.562%
Intellia Therapeutics, Inc. -398.79 Million USD 100.555%
Zoetis Inc. 5.83 Billion USD 99.962%
Abeona Therapeutics Inc. 302 Thousand USD -633.444%
Mettler-Toledo International Inc. 2.16 Billion USD 99.898%
BioMarin Pharmaceutical Inc. 1.9 Billion USD 99.884%
Vertex Pharmaceuticals Incorporated 8.6 Billion USD 99.974%
Kala Pharmaceuticals, Inc. -303 Thousand USD 831.023%
Ionis Pharmaceuticals, Inc. 778.51 Million USD 99.715%
Atara Biotherapeutics, Inc. -313 Thousand USD 807.668%
Verastem, Inc. -62 Thousand USD 3672.581%
Nektar Therapeutics 53.47 Million USD 95.858%
Axsome Therapeutics, Inc. 244.53 Million USD 99.094%
Aclaris Therapeutics, Inc. -85.21 Million USD 102.599%
Sarepta Therapeutics, Inc. 1.09 Billion USD 99.797%
OPKO Health, Inc. 318.12 Million USD 99.304%
Exelixis, Inc. 1.75 Billion USD 99.874%
Neurocrine Biosciences, Inc. 1.84 Billion USD 99.88%
Corcept Therapeutics Incorporated 475.89 Million USD 99.535%
Anavex Life Sciences Corp. - USD -Infinity%
Imunon, Inc. -720 Thousand USD 407.637%
Blueprint Medicines Corporation 236.58 Million USD 99.064%
Insmed Incorporated 239.63 Million USD 99.076%
Halozyme Therapeutics, Inc. 636.89 Million USD 99.652%
Agios Pharmaceuticals, Inc. 17.31 Million USD 87.211%
TG Therapeutics, Inc. 219.1 Million USD 98.989%
Incyte Corporation 3.44 Billion USD 99.936%
Emergent BioSolutions Inc. 343.9 Million USD 99.356%